The short answer
A point estimate quoted without its interval is close to meaningless. A 2025 meta-analysis reported a risk ratio of 0.568, which looks protective, with a confidence interval spanning a 92% reduction to a 320% increase, and heterogeneity of 98% between its studies.
Key facts
- Reported risk ratio
- 0.568
- 95% confidence interval
- 0.077 to 4.205
- Lower bound in plain terms
- 92% lower risk
- Upper bound in plain terms
- 320% higher risk
- Heterogeneity
- I-squared = 98%
- Studies pooled in that estimate
- 4
- Studies screened
- 126
- Source
- Bushi G et al., Diabetes Metab Res Rev 2025 (PMID 39945396)
The number and its interval
Bushi and colleagues screened 126 studies, included 11, and pooled four of them for a meta-analysis of suicidal outcomes among GLP-1 receptor agonist users against users of other anti-hyperglycaemic drugs. The result was a risk ratio of 0.568, with a 95% confidence interval of 0.077 to 4.205. Quoted alone, 0.568 reads as a 43% reduction in risk and would make a reassuring headline. Quoted with its interval, it says the data are compatible with the drugs reducing risk by 92%, with them increasing it more than fourfold, and with everything in between including no effect at all.
What a confidence interval is actually reporting
It is a statement about the precision of an estimate, not about the probability that a particular value is true. That distinction is routinely blurred and worth keeping. The practical reading is this: values inside the interval are those the data cannot reasonably exclude. An interval that contains 1 means no effect cannot be excluded. An interval running from 0.077 to 4.205 additionally means that a large protective effect and a large harmful effect cannot be excluded either. The width of the interval is the finding here, far more than its centre.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the point estimate misleads more than a null result would
A study reporting no difference invites the correct conclusion: this did not settle the question. A study reporting 0.568 invites a wrong one, because a specific number carries an air of measurement. The centre of a very wide interval is not a best guess in any useful sense. It is where the arithmetic happened to land given a handful of studies that disagreed with each other. The asymmetry in how these get reported is predictable: 0.568 travels, 0.077-to-4.205 does not.
The heterogeneity statistic is the second warning
I-squared estimates what share of the variation between studies exceeds what chance alone would produce. Values above 75% are conventionally described as considerable heterogeneity. This analysis reported 98%. At that level the included studies are not measuring the same thing in the same way, and pooling them produces an average of incommensurable quantities. A high I-squared does not merely widen the interval. It undermines the premise that a single summary number exists to be estimated. The authors say so, noting that the high heterogeneity and reliance on pharmacovigilance data suggest caution.
What did settle the question, and why
The FDA's review of the same question used a different kind of evidence: a meta-analysis of 91 placebo-controlled clinical trials across GLP-1 receptor agonist development programmes, comprising 107,910 participants of whom 60,338 received a GLP-1 receptor agonist and 47,572 received placebo. Randomised allocation removes confounding by indication; a hundred thousand participants supplies precision; and pooling trials with comparable designs keeps heterogeneity manageable. Four heterogeneous observational studies could not answer this. Ninety-one randomised trials could. The difference is design and scale, not the direction of the result.
A habit worth forming
Whenever a relative risk, odds ratio, hazard ratio or risk ratio is quoted, ask for the interval before doing anything else with the number. If the interval is not given, the number should not be used. If the interval crosses 1, the study did not demonstrate a difference regardless of where the point estimate sits. And if the interval spans an order of magnitude, the honest summary is that the analysis was uninformative, which is a legitimate finding and a much better one to report than a spurious point estimate.
Quick reference
| Bushi 2025 meta-analysis | FDA trial-level meta-analysis | |
|---|---|---|
| Evidence type | Observational studies | Placebo-controlled randomised trials |
| Studies pooled | 4 (of 11 included, 126 screened) | 91 |
| Participants | Not pooled as a single figure | 107,910 |
| Treated / comparator | Mixed comparators | 60,338 / 47,572 |
| Heterogeneity | I-squared 98% | Comparable trial designs |
| Conclusion supported | Uninformative | No increased risk detected |
Frequently asked questions
Is a wide interval the researchers' fault?
Usually not. It reflects how much information the available studies contained. Reporting it openly, as this paper did, is the correct behaviour. The failure happens downstream, when the point estimate is quoted without it.
Does I-squared of 98% mean the studies are wrong?
No, it means they differ from each other far more than chance explains, because of different populations, comparators, outcome definitions or designs. Any of those can be individually reasonable while making the studies unpoolable.
Why does randomisation help so much here?
Because the alternative explanation for any association between these drugs and psychiatric outcomes is that people who receive them differ from people who do not, in ways related to the outcome. Randomisation removes that by construction; statistical adjustment in observational data can only remove what was measured.
Should observational studies be ignored?
No. They answer questions trials cannot, including what happens over longer periods and in people trials exclude. The point is to match the strength of a claim to the design that produced it, and a four-study pool with 98% heterogeneity supports a very weak claim.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBushi G et al., Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis - Diabetes Metab Res Rev 2025 (PMID 39945396)pubmed.ncbi.nlm.nih.gov
- FDAFDA Drug Safety Communication: FDA requests removal of suicidal behavior and ideation warning from GLP-1 receptor agonist medications, 13 January 2026fda.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Adding a Warning Needs Suspicion; Removing One Needs EvidenceRegulators added a suicidality warning to GLP-1 labels on suspicion alone. Removing it again took two and a half years and a review of 91 randomised trials.
- The Receptors That Decide When GLP-1 Comes OutGlucose, fat and fermentation products are each detected by a different sensor on the same cell, and none of them works quite the way most explanations assume.
- The Nerve That Reads GLP-1 Before the Blood DoesKnocking down GLP-1 receptors on vagal afferents changed meal size and gastric emptying but not long-term body weight. That distinction matters enormously.
- Why Where Bile Arrives Changes How Much GLP-1 Comes OutBile acids are signalling molecules as well as detergents. They act on a receptor on L cells, and delivering them further down the gut raises the response.
- Two Nearly Identical Cells Releasing Opposite-Tempered HormonesGIP and GLP-1 come from different cells that are transcriptomically close and share a glucose sensor. The differences between them are small but exploitable.